Amyloid-PET scanning has misled the FDA into granting approval for Aduhelm

By | November 16, 2022
Last year, the FDA gave accelerated approval of the antibody aducanumab (marketed as Aduhelm by Biogen) for the treatment of Alzheimer’s disease.